KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Consolidated Net Income (2018 - 2025)

Esperion Therapeutics' Consolidated Net Income history spans 8 years, with the latest figure at $62.6 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 315.28% year-over-year to $62.6 million; the TTM value through Dec 2025 reached -$24.3 million, down 85.96%, while the annual FY2025 figure was -$22.6 million, 56.25% up from the prior year.
  • Consolidated Net Income reached $62.6 million in Q4 2025 per ESPR's latest filing, up from -$32.0 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $62.6 million in Q4 2025 to a low of -$90.9 million in Q1 2021.
  • Average Consolidated Net Income over 5 years is -$38.1 million, with a median of -$47.6 million recorded in 2021.
  • The largest YoY upside for Consolidated Net Income was 315.28% in 2025 against a maximum downside of 171.3% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at -$69.1 million in 2021, then rose by 17.69% to -$56.8 million in 2022, then decreased by 1.02% to -$57.4 million in 2023, then soared by 49.36% to -$29.1 million in 2024, then soared by 315.28% to $62.6 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Consolidated Net Income are $62.6 million (Q4 2025), -$32.0 million (Q3 2025), and -$13.4 million (Q2 2025).